PubRank

Laetitia Dahan

Author PubWeight™ 37.87‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011 11.93
2 Cytidine deaminase residual activity in serum is a predictive marker of early severe toxicities in adults after gemcitabine-based chemotherapies. J Clin Oncol 2009 1.69
3 Prognostic impact of the extracapsular lymph node involvement on disease-free survival according to the 7th edition of American Joint Committee on Cancer Staging System. Eur J Cardiothorac Surg 2013 1.50
4 Time until definitive quality of life score deterioration as a means of longitudinal analysis for treatment trials in patients with metastatic pancreatic adenocarcinoma. Eur J Cancer 2010 1.30
5 High histone deacetylase 7 (HDAC7) expression is significantly associated with adenocarcinomas of the pancreas. Ann Surg Oncol 2008 1.18
6 Integrating pharmacogenetics into gemcitabine dosing--time for a change? Nat Rev Clin Oncol 2011 1.02
7 Extracapsular lymph node involvement is a negative prognostic factor after neoadjuvant chemoradiotherapy in locally advanced esophageal cancer. J Thorac Oncol 2009 0.99
8 Treatment of advanced hepatocellular carcinoma with long-acting octreotide: a phase III multicentre, randomised, double blind placebo-controlled study. Eur J Cancer 2009 0.99
9 Routine dihydropyrimidine dehydrogenase testing for anticipating 5-fluorouracil-related severe toxicities: hype or hope? Clin Colorectal Cancer 2010 0.98
10 DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity. Cancer Chemother Pharmacol 2010 0.97
11 Toxic death case in a patient undergoing gemcitabine-based chemotherapy in relation with cytidine deaminase downregulation. Pharmacogenet Genomics 2007 0.96
12 Toxic death-case after capecitabine + oxaliplatin (XELOX) administration: probable implication of dihydropyrimidine deshydrogenase deficiency. Cancer Chemother Pharmacol 2005 0.95
13 The added value of quality of life (QoL) for prognosis of overall survival in patients with palliative hepatocellular carcinoma. J Hepatol 2012 0.94
14 Respiratory complications after oesophagectomy for cancer do not affect disease-free survival. Eur J Cardiothorac Surg 2012 0.93
15 Development and validation of a new prognostic score of death for patients with hepatocellular carcinoma in palliative setting. J Hepatol 2010 0.91
16 A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy. Ther Drug Monit 2006 0.91
17 Cetuximab after bevacizumab in metastatic colorectal cancer: is it the best sequence? Dig Liver Dis 2011 0.89
18 Expression of adrenomedullin in human colorectal tumors and its role in cell growth and invasion in vitro and in xenograft growth in vivo. Cancer Med 2013 0.85
19 Patients with brain metastases from colorectal cancer are not condemned. Anticancer Res 2013 0.85
20 Indications and outcome of salvage surgery for oesophageal cancer. Eur J Cardiothorac Surg 2008 0.84
21 Rapid deaminator status is associated with poor clinical outcome in pancreatic cancer patients treated with a gemcitabine-based regimen. Pharmacogenomics 2013 0.83
22 Biweekly docetaxel, fluorouracil, leucovorin, oxaliplatin (TEF) as first-line treatment for advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: safety and efficacy in a multicenter cohort. Gastric Cancer 2013 0.82
23 Targetting esophageal and gastric cancers with monoclonal antibodies. Curr Top Med Chem 2012 0.80
24 NADPH oxidase 1 controls the persistence of directed cell migration by a Rho-dependent switch of alpha2/alpha3 integrins. Mol Cell Biol 2009 0.80
25 Pancreatic cancer and pancreaticoduodenectomy in elderly patient: morbidity and mortality are increased. Is it the real life? Hepatogastroenterology 2009 0.79
26 Esophagus cancer. Gastroenterol Clin Biol 2006 0.78
27 Impact of neoadjuvant chemoradiation on lymph node status in esophageal cancer: post hoc analysis of a randomized controlled trial. Ann Surg 2015 0.78
28 Body mass index kinetics and risk factors of malnutrition one year after radical oesophagectomy for cancer. Eur J Cardiothorac Surg 2012 0.77
29 Letter to the editor: pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism. Eur J Clin Pharmacol 2010 0.76
30 Uracil-tegafur/leucovorin and mitomycin C salvage therapy in patients with advanced colorectal cancer: a phase II study. J Chemother 2012 0.75
31 Impact of venous thromboembolism on the natural history of pancreatic adenocarcinoma. Hepatobiliary Pancreat Dis Int 2015 0.75
32 Pemetrexed in pancreatic cancer. Oncology (Williston Park) 2004 0.75
33 First-Line Chemotherapy for Metastatic Esophageal Squamous Cell Carcinoma: Clinico-Biological Predictors of Disease Control. Oncology 2016 0.75
34 Experience of two trauma-centers with pancreatic injuries requiring immediate surgery. Hepatogastroenterology 2008 0.75
35 Population pharmacokinetics of gemcitabine and dFdU in pancreatic cancer patients using an optimal design, sparse sampling approach. Ther Drug Monit 2017 0.75